MedTrace Logo

AAV8-hCocH for Cocaine Use Disorder

NCT04884594 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-03-27

No results posted yet for this study

Summary

The purpose of this study is to test the safety of a novel gene viral vector treatment for adults with cocaine use disorder-sustained remission. This gene regulates an enzyme (cocaine hydrolase) that breaks down cocaine into inactive substances, thereby decreasing the pleasurable feeling this drug usually provides.

Conditions

  • Cocaine Dependence, in Remission

Interventions

DRUG

AAV8-hCocH

2e12 vg/kg single infusion intravenous

DRUG

AAV8-hCocH

6e12 vg/kg single infusion intravenous

DRUG

AAV8-hCocH

4e12 vg/kg single infusion intravenous

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • W. Michael Hooten

    lead OTHER

Principal Investigators

  • W. Michael Hooten, MD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-08
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04884594 on ClinicalTrials.gov